Tuesday, July 13, 2021

Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market


With oligonucleotides on the rise to treat rare diseases and cancers, Japanese manufacturer Nitto Denko is laying big plans. 

Nitto will plug a whopping 25 billion yen ($225.93 million) into its Massachusetts-based subsidiary Nitto Denko Avecia, plus other companies in its fold, to beef up oligonucleotide production amid fast-growing demand. The cash will cover new buildings, a new commercial drug substance manufacturing line, and stepped-up process and analytical development at Avecia’s home base in Milford, Massachusetts, Nitto said in a release. 

The process development building is expected to kick off operations this year, while the commercial manufacturing building and production line are set to go live in early 2023, Nitto said. Meanwhile, Nitto is already planning to invest another 25 billion yen to boost capacity for polymer supports used to make oligonucleotide therapeutics and expand its production line to scale up clinical production. 

RELATED: Japan’s Ajinomoto Bio-Pharma Services takes control of GeneDesign

Nitto Denko bought Avecia in 2011, but the Massachusetts operation has been in the oligonucleotide game for more than 20 years. Avecia now tackles manufacturing from its facilities in Milford and Cincinnati, Ohio, and says on its website that it can produce a range of oligonucleotides, including small interfering RNA (SiRNA), short hairpin RNA (ShRNA) and microRNA (MiRNA).

After folding in Avecia, Nitto continued to build out its manufacturing, formulation and analytical offerings. Back in 2017, Avecia debuted a 20,000-square-foot upgrade to its Milford oligonucleotide active pharmaceutical ingredient (API) plant, bringing on extra office and manufacturing space. At the time, Avecia trumpeted the plant as the world’s largest oligonucleotide ingredients manufacturing site. 

Other CDMOs are muscling into the field, too. WuXi STA in January of 2020 christened a large-scale oligonucleotide API manufacturing unit at its site in Changzhou, China. WuXi pointed to mounting interest in nucleic acid drugs over the past several years, describing the field as “a hot area.”



Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...